Abstract
Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.
| Original language | English |
|---|---|
| Pages (from-to) | 238-248 |
| Number of pages | 11 |
| Journal | Nuklear Medizin - Isotope In Medizin und Biologie |
| Volume | 17 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Dec 1978 |
| Externally published | Yes |
Fingerprint
Cite this
}
Clinical evaluation of radio-labelled bleomycin for tumor detection. / Rasker, J.J.; Beekhuis, H.; van de Poll, M.A.P.C.; Versluis, A.; Jurjens, H.; Woldring, M.G.
In: Nuklear Medizin - Isotope In Medizin und Biologie, Vol. 17, No. 6, 01.12.1978, p. 238-248.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Clinical evaluation of radio-labelled bleomycin for tumor detection
AU - Rasker, J.J.
AU - Beekhuis, H.
AU - van de Poll, M.A.P.C.
AU - Versluis, A.
AU - Jurjens, H.
AU - Woldring, M.G.
PY - 1978/12/1
Y1 - 1978/12/1
N2 - Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.
AB - Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.
UR - http://www.scopus.com/inward/record.url?scp=0018216942&partnerID=8YFLogxK
U2 - 10.1055/s-0037-1620700
DO - 10.1055/s-0037-1620700
M3 - Article
C2 - 84374
AN - SCOPUS:0018216942
VL - 17
SP - 238
EP - 248
JO - Nuklearmedizin
JF - Nuklearmedizin
SN - 0029-5566
IS - 6
ER -